Showing results (31-40 of 86) with videos related to
Sort By:
Pageof 9
Breast Cancer Research and Treatment|January 15, 2008
Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG)Zsuzsanna Kahán, Stanislav Spanik, Maria Wagnerova, et al.Scientific Reports|September 21, 2016
Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcomaRichard Schwameis, Christoph Grimm, Thomas Brodowicz, et al.Cancer Science|May 23, 2014
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancerGerald W Prager, Kira H Braemswig, Alexandra Martel, et al.Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Sequential Administration of Interferon-gamma, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II TrialManuela Schmidinger, Guenther Steger, Catharina Wenzel, et al.Anticancer Research|August 10, 2002
Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatinMaria Flamm, Thomas Brodowicz, Andrea Haitel, et al.Wiener Klinische Wochenschrift|October 18, 2019
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in AustriaAndreas Seeber, Lukas Weiss, Franz Romeder, et al.Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|April 28, 2018
C-reactive protein: An independent predictor for dedifferentiated chondrosarcomaElena Nemecek, Philipp Theodor Funovics, Gerhard Martin Hobusch, et al.BMC Cancer|February 19, 2016
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trialChristiane Thallinger, Istvan Lang, Cvetka Grasic Kuhar, et al.British Journal of Cancer|December 15, 2015
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancerChristoph Zielinski, Istvan Lang, Semir Beslija, et al.Oncology|July 8, 2011
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancerAlíz Nikolényi, Farkas Sükösd, László Kaizer, et al.Pageof 9